331 related articles for article (PubMed ID: 3088461)
1. [Hyperammonemia in valproate therapy in children and adolescents].
Laub MC
Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
[TBL] [Abstract][Full Text] [Related]
2. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
Hamed SA; Abdella MM
Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
[TBL] [Abstract][Full Text] [Related]
4. Valproate-induced hyperammonemia.
Batshaw ML; Brusilow SW
Ann Neurol; 1982 Mar; 11(3):319-21. PubMed ID: 6807193
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for hyperammonemia in pediatric patients with epilepsy.
Yamamoto Y; Takahashi Y; Imai K; Mishima N; Yazawa R; Inoue K; Itoh K; Kagawa Y; Inoue Y
Epilepsia; 2013 Jun; 54(6):983-9. PubMed ID: 23409971
[TBL] [Abstract][Full Text] [Related]
6. Effects of valproate, carbamazepine, and levetiracetam on the antioxidant and oxidant systems in epileptic patients and their clinical importance.
Varoglu AO; Yildirim A; Aygul R; Gundogdu OL; Sahin YN
Clin Neuropharmacol; 2010 May; 33(3):155-7. PubMed ID: 20502135
[TBL] [Abstract][Full Text] [Related]
7. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy.
Pylvänen V; Pakarinen A; Knip M; Isojärvi J
Epilepsy Behav; 2006 May; 8(3):643-8. PubMed ID: 16600693
[TBL] [Abstract][Full Text] [Related]
8. Thyroid function in children with epilepsy treated with sodium valproate monotherapy: a prospective study.
Attilakos A; Katsarou E; Prassouli A; Mastroyianni S; Voudris K; Fotinou A; Garoufi A
Clin Neuropharmacol; 2009; 32(1):32-4. PubMed ID: 18978499
[TBL] [Abstract][Full Text] [Related]
9. [Role of hyperammonemia in stuporous states induced by sodium valproate].
Warter JM; Marescaux C; Rumbach L; Micheletti G; Chabrier G; Koehl C; Imler M; Collard M
Rev Neurol (Paris); 1983; 139(12):753-7. PubMed ID: 6420866
[TBL] [Abstract][Full Text] [Related]
10. The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist?
Chicharro AV; de Marinis AJ; Kanner AM
Epilepsy Behav; 2007 Nov; 11(3):361-6. PubMed ID: 17845866
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.
Yamamoto Y; Takahashi Y; Suzuki E; Mishima N; Inoue K; Itoh K; Kagawa Y; Inoue Y
Epilepsy Res; 2012 Sep; 101(3):202-9. PubMed ID: 22542569
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of the ketogenic diet in pediatric epilepsy: effects of valproate combination therapy.
Lyczkowski DA; Pfeifer HH; Ghosh S; Thiele EA
Epilepsia; 2005 Sep; 46(9):1533-8. PubMed ID: 16146450
[TBL] [Abstract][Full Text] [Related]
13. No effect of co-administered antiepileptic drugs on in-vivo protein binding parameters of valproic acid in patients with epilepsy.
Suzuki Y; Itoh H; Abe T; Nishimura F; Sato Y; Takeyama M
J Pharm Pharmacol; 2011 Jul; 63(7):976-81. PubMed ID: 21635265
[TBL] [Abstract][Full Text] [Related]
14. Serum lipids, vitamin B12 and folic acid levels in children receiving long-term valproate therapy.
Geda G; Caksen H; Içağasioğlu D
Acta Neurol Belg; 2002 Sep; 102(3):122-6. PubMed ID: 12400250
[TBL] [Abstract][Full Text] [Related]
15. Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs.
Ratnaike RN; Schapel GJ; Purdie G; Rischbieth RH; Hoffmann S
Br J Clin Pharmacol; 1986 Jul; 22(1):100-3. PubMed ID: 3091053
[TBL] [Abstract][Full Text] [Related]
16. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
Tseng YL; Huang CR; Lin CH; Lu YT; Lu CH; Chen NC; Chang CC; Chang WN; Chuang YC
Medicine (Baltimore); 2014 Sep; 93(11):e66. PubMed ID: 25192484
[TBL] [Abstract][Full Text] [Related]
18. [Hyperammonemic encephalopathy associated with valproate acid].
Osuna MT; Burcet J; Ramió L; Ustrell X; Silva Y; Molins A
Neurologia; 2003; 18(6):347-50. PubMed ID: 12838456
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for development of subclinical hypothyroidism during valproic acid therapy.
Mikati MA; Tarabay H; Khalil A; Rahi AC; El Banna D; Najjar S
J Pediatr; 2007 Aug; 151(2):178-81. PubMed ID: 17643774
[TBL] [Abstract][Full Text] [Related]
20. Subclinical hypothyroidism during valproic acid therapy in children and adolescents with epilepsy.
Kim SH; Chung HR; Kim SH; Kim H; Lim BC; Chae JH; Kim KJ; Hwang YS; Hwang H
Neuropediatrics; 2012 Jun; 43(3):135-9. PubMed ID: 22618302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
